Omeros (OMER) – Analyst EPS Change
-
Omeros Corp's (OMER) Narsoplimab Approval Pathway is More Challenging, PT Lowered to $12 at BofA Securities
-
Cantor Fitzgerald Maintains Neutral & $15 PT on Omeros (OMER) Following 'Breakthrough Therapy Designation Provides Validation for OMS721 in IgA Nephropathy'
-
-
-
-
-
-
Back to OMER Stock Lookup